Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Is Ambarella, Inc. All Hype or Is Its CV Chip All That?

By Chris Lau, InvestorPlace Contributor

Ambarella stock is stuck in a range until the company releases its CV1 chip to the market, which it is planning for later this year. As AMBA targets the security camera market and autonomous driving, revenue from chip sales could jump.

Dropbox, Inc. Stock Set to Rocket Higher Even After a Successful IPO

By Chris Lau, InvestorPlace Contributor

DBX may look like an expensive, hyped technology stock, but its user growth is very real. Though risky, the odds of Dropbox disappointing investors are low.

Lam Research Corporation Prepped for Growth Into Earnings

By Chris Lau, InvestorPlace Contributor

Lam Research stock will likely report another blowout quarter, thanks to strong demand for LRCX's chips for memory and storage.

AbbVie Inc. Is a Clear Value Play in Biotech Stocks

By Chris Lau, InvestorPlace Contributor

AbbVie stock is not bouncing back after investors bailed on it following potentially negative clinical results. For value investors, ABBV trades at a discount to its peers but investors seem skittish of biotech's risks. When that changes, ABBV stock will be one of the first to recover.

Tandem Diabetes Care Inc Is Up 194% — And It’s Not Done Yet

By Chris Lau, InvestorPlace Contributor

Tandem Diabetes is firing on all cylinders and markets are already noticing. TNDM has more growth ahead than is currently priced into the stock.

Load More